Sept 24 (Reuters) - U.S. Senator Bernie Sanders said on

Tuesday that he had received commitments from major pharmacy

benefit managers (PBMs) that they would expand coverage of Novo

Nordisk's weight-loss drugs if the company lowered

their list prices.

"I have received commitments in writing from all of the

major PBMs that if Novo Nordisk substantially reduced the list

price for (the drugs), they would not limit coverage. In fact,

all of them told me they would be able to expand coverage," he

said.

The remarks come as Novo Nordisk's CEO Lars Jorgensen speaks

at a hearing of the Senate Committee on Health, Education, Labor

and Pensions, which is chaired by Sanders.